Volume 1.28 | Jul 30

Prostate Cell News 1.28, July 30, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


TOP STORY

A New Ground Zero for Prostate Cancer 
A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer. [Press release from Howard Hughes Medical Institute discussing online prepublication in Science]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 




SCIENCE NEWS

Profile of Low-Risk Prostate Cancer Patients Shows Most Receive Aggressive Treatment
Findings show that most men with prostate cancer who tested below the normal PSA level and had low-risk disease nevertheless underwent aggressive treatment. [Press release from The Cancer Institute of New Jersey discussing online prepublication in the Archives of Internal Medicine]

Gel Targets Prostate Cancer
Itaru Hamachi and colleagues at Kyoto University have developed a supramolecular hydrogel that could provide a more accurate way of detecting cancer in prostate glands. [Press release from RSC Publishing discussing online prepublication in Chemical Science]

Cedars-Sinai’s Samule Oschin Comprehensive Cancer Institute Has New GPS-Like System That Delivers More Focused Radiation to Prostate Cancer Tumors
A new system that utilizes a precise GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. [Press release from Cedars-Sinai’s Samule Oschin Comprehensive Cancer Institute]

New Clinical Trial Offers Vascular-Targeted Photodynamic Therapy to Patients with Localized Prostate Cancer
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer.  This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells. [Press release from New York University Langone Medical Center]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies

 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 




CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Identification of a Cell of Origin from Human Prostate Cancer
Here, scientists show that basal cells from primary benign human prostate tissues can initiate prostate cancer in immunodeficient mice. [Nature]

89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
In this study, investigators reported the preparation of 89Zr-desferrioxamine B (DFO)-J591, a novel 89Zr-labeled monoclonal antibody construct for targeted immunoPET and quantification of prostate-specific membrane antigen expression in vivo. [J Nucl Med]

Cannabinoid Receptor Dependent and Independent Anti-Proliferative Effects of Omega-3 Ethanolamides in Androgen Receptor Positive and Negative Prostate Cancer Cell Lines
Findings suggest that the expression of cannabinoid receptors and of fatty acid amide hydrolase in some tumour cells could well influence the effectiveness of docosahexaenoic acid and eicosapentaenoic acid or their ethanolamide derivatives as anticancer agents. [Carcinogenesis]

Effects of Titanocene Dichloride Derivatives on Prostate Cancer Cells, Specifically DNA Damage-Induced Apoptosis
In this study, the effects of novel derivatives of titanocene dichloride on prostate cancer cell lines have been investigated. [Prostate]

Characterisation of Prostate Cancer Lesions in Heterozygous Men1 Mutant Mice
Using immunostaining for the androgen receptor and p63, scientists demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in prostate cancer lesions. [BMC Cancer]

Short Rare hTERT-VNTR 2-2nd Alleles are Associated with Prostate Cancer Susceptibility and Influence Gene Expression
The hTERT (human telomerase reverse transcriptase) gene contains five variable number tandem repeats (VNTR) and previous studies have described polymorphisms for hTERT-VNTR2-2nd. Researchers investigated how allelic variation in hTERT-VNTR2-2nd may affect susceptibility to prostate cancer. [BMC Cancer]

Supramolecular Hydrogel Capsule Showing Prostate Specific Antigen-Responsive Function for Sensing and Targeting Prostate Cancer Cells
Investigators constructed the functional SH-capsule 1/2 that can release a model fluorescent drug triggered by prostate specific antigen (PSA)-catalyzed proteolysis. Selective release of the fluorescent substance was exploited to both assay PSA activity and detect prostate cancer (PCa) cells. They also demonstrated that the released fluorescent substance was delivered and internalized into the PCa cells, mediated by binding to the membrane-bound protein prostate-specific membrane antigen, which is over-expressed on a plasma membrane of the PCa cells. [Chem Sci]

CLINICAL RESEARCH

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
In this double-blind, placebo-controlled, multicenter phase 3 trial, researchers randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. [N Engl J Med]

Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
Most men diagnosed as having prostate cancer with a prostate-specific antigen threshold below 4.0 ng/mL had low-risk disease but underwent aggressive local therapy. Lowering the biopsy threshold but retaining the inability to distinguish indolent from aggressive cancers might increase the risk of overdiagnosis and overtreatment. [Arch Intern Med]

Dynamic Contrast-enhanced CT for Cancer: Relationship Between Image Noise, Voxel Size, and Repeatability
The purpose of the study was to evaluate the relationship between image noise, voxel size, and voxel-wise repeatability of a dynamic contrast agent–enhanced computed tomographic (CT) examination for prostate cancer. [Radiology]

Efficient Assessment of the Most Important Symptoms in Advanced Prostate Cancer: the NCCN/FACT-P Symptom Index
In line with recent regulatory guidance on the development of patient-reported outcomes, investigators undertook a multistep/multistudy approach to develop and test a new symptom index (NCCN FACT-Prostate Symptom Index-17) that can be used to examine the effectiveness of noncurative treatments in advanced prostate cancer. [Psychooncology]




INDUSTRY NEWS

Jevtana® (cabazitaxel) Injection Now Available in the U.S.
Sanofi-aventis announced that Jevtana® (cabazitaxel) Injection is now available in the United States for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based treatment regimen. [Sanofi-aventis Press Release]

AMD Appoints BK Medical as Agent for Prostate HistoScanning™ in the UK
Advanced Medical Diagnostics (AMD) SA announced that it has appointed BK Medical UK Ltd as sole agent for Prostate HistoScanning™ in the UK. [Advanced Medical Diagnostics SA Press Release]

iCAD Unveils Advanced MRI Product Suite
iCAD, Inc. announced the launch of an MRI product suite for breast, prostate, and other organs. [iCAD, Inc. Press Release]

New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
Dendreon Corporation announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE(R) (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. [Dendreon Corporation Press Release discussing online prepublication in the New England Journal of Medicine]




POLICY NEWS 

Brussels to Invest $8.3 Billion in Research
Research organizations, universities, and industry will receive a sum of 6.4 billion euros next year in the European Commission’s largest ever allocation for research and innovation. [European Commission, European Union]

Consumer Gene Test Results Misleading – U.S. Probe
People who send off their saliva to genetic testing companies to find out their risk for prostate cancer or diabetes are likely to get different results, depending on the company they choose, government investigators told lawmakers. [Government Accountability Office, United States]

FDA and Other Federal Agencies Collaborate to Improve Chemical Screening
The Tox21 collaboration merges federal agency resources (research, funding and testing tools) to develop ways to more effectively predict how chemicals will affect human health and the environment. [Food and Drug Administration, United States]

Gene-Testing Companies May Need U.S. Regulators Review, FDA Letters Say
The U.S. Food and Drug Administration sent letters to gene-testing companies saying the tests “appear to meet the definition of a device.” [Food and Drug Administration, United States]

NIH Asks for Input on Closing Loophole in Conflict-of-Interest Rule
Responding to yet another flap about the influence of drug companies on biomedical research, the National Institutes of Health (NIH) has decided it needs more time to revise its rules for policing conflicts of interest so that sanctions will move with an investigator if he or she changes institutions. [National Institutes of Health, United States]

Office of Biotechnology Activities; Recombinant DNA Research: Proposed Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (Doc. 2010-17668) [National Institutes of Health, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (Doc. 2010-18088) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (Doc. 2010-18052) [National Institutes of Health, United States]

Genomics of Transplantation Cooperative Research Program (U01, U19) (RFA-AI-10-019) [National Institutes of Health, United States]

Instrument Development for Biomedical Applications (R21) (RFA-RR-10-009) [National Institutes of Health, United States]

Biosafety in Microbiological and Biomedical Laboratories (BMBL): 5th Edition (NOT-OD-10-117) [National Institutes of Health, United States]

Bioengineering Research Partnerships (BRP)[R01] (PAR-10-234) [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering Program Project (P01) Applications (PAR-10-233) [National Institutes of Health, United States] 

Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors [Docket Number NIH-2010-0001] [Department of Health and Human Services, United States]




EVENTS (Listed by Date)

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

9th Mount Desert Island Stem Cell Symposium
August 6-7, 2010
Salsbury Cove, United States

Australian-Canadian Prostate Cancer Research Alliance Symposium
August 6-8, 2010
Gold Coast, Australia

NEW 11th National Prostate Cancer Symposium
August 11-13, 2010
Melbourne, Australia

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
California, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

NEW 2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada


35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us